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Abstract
Background: The pathogenesis of biliary cancers is ill-defined. This study investigates changes in
gene expression and copy number in biliary cancers and correlates these changes with anatomical
site of origin, histopathology and outcome.
Methods: We performed gene expression and CGH analysis on 34 biliary tract cancer specimens.
Results were confirmed by RT-PCR. Clinical-pathologic correlation was made using functional
over-representation analysis of the top 100 mutations associated with each variable.
Results: There were 545 genes with altered expression in extrahepatic cholangiocarcinoma, 2,354
in intrahepatic cholangiocarcinoma, and 1,281 in gallbladder cancer. Unsupervised hierarchical
clustering analysis indicated there was no difference in the global gene expression patterns between
each biliary cancer subgroup. CGH analysis revealed that short segments of chromosomes 1p, 3p,
6q, 8p, 9p, and 14q were commonly deleted across all cancer subtypes. Commonly amplified
regions included segments of 1q, 3q, 5p, 7p, 7q, 8q, and 20q. Over-representation analysis revealed
an association between altered expression of functional gene groupings and pathologic features.
Conclusion: This study defined regions of the genome associated with changes in DNA copy
number and gene expression in specific subtypes of biliary cancers. The findings have implications
for identification of therapeutic targets, screening, and prognostication.
Background
Biliary tract cancers account for approximately 10–20% of
hepatobiliary neoplasms. Approximately 9,000 cases of
biliary tumors are diagnosed in the USA each year. Gall-
bladder carcinoma (GBC) is the most common, account-
ing for 60% of cases [1]. The remaining 40% are
cholangiocarcinomas and are further sub-classified as int-
rahepatic (IHC) when they arise from intrahepatic biliary
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radicles or extrahepatic (EHC) when they arise from the
confluence of the main left and right hepatic ducts or dis-
tal in the bile ducts. The classification of biliary tract can-
cers into these anatomically-based subtypes has
substantial clinical relevance, as risk factors, presentation,
staging, and treatment varies for each [2,3]. Regardless of
subtype, most patients with carcinoma of the biliary tract
present with advanced disease, with median survival of
approximately one to two years from the time of diagnosis
[4-6].
Little is known regarding the genetic alterations in the bil-
iary epithelium that lead to cancer. Studies have shown
that biliary carcinogenesis may be related in-part to loss of
heterozygosity at the loci of chromosomes 1p, 6q, 9p,
16q, and 17p, and point mutations at the K-ras oncogene
and the p-53 tumor suppressor gene [7,8]. Enhanced
expression of VEGF in cholangiocarcinoma cells and
localization of VEGF receptor-1 and receptor-2 in
endothelial cells is thought to play a crucial role in tumor
progression [9]. Clyclooxygenase-2 and c-erbB-2 are also
overexpressed in cholangiocarcinoma [10]. In addition,
interleukin-6 is important in the proliferation of malig-
nant biliary epithelial cells [11,12]. Our recent work
examining cell cycle-regulatory protein expression in bil-
iary tract cancers revealed differentially expressed cell
cycle-regulatory proteins based on tumor location and
morphology, and an overlap in the pathogenesis of GBC
and EHC was suggested [13].
The present study investigates alterations in gene expres-
sion and gene copy number in frozen tumor specimens
from patients with GBC, IHC, and EHC. Gene expression
results were correlated with comparative genomic hybrid-
ization (CGH) data by identifying transcriptional changes
in the most highly unstable genomic regions. Addition-
ally, the genetic findings were correlated with clinical dis-
ease characteristics and pathologic features.
Methods
Patients and specimens
Biliary tract cancers from 34 patients (13 IHC, 12 EHC, 9
GBC) were snap-frozen and stored at -80°C. In addition 9
non-cancerous gallbladders and 9 non-cancerous bile
duct controls were obtained from patients who had resec-
tions for diseases not involving the gallbladder or bile
duct (in these patients the gallbladder or bile duct was
removed for surgical access to other hepatobiliary or pan-
creatic structures). Each sample was re-examined histolog-
ically using H&E-stained cryostat sections. Surrounding
non-neoplastic tissue was dissected from the frozen block
under 10× magnification and care was taken that at least
90% for remaining cells were cancerous. All studies were
approved by the Memorial Sloan-Kettering IRB.
RNA isolation, probe preparation, and expression 
microarray hybridization
Total RNA was isolated from tissue using the DNA/RNA
all prep kit (Qiagen, Germantown, Maryland, USA).
Quality of RNA was ensured before labeling by analyzing
20–50 ng of each sample using the RNA 6000 NanoAssay
and a Bioanalyzer 2100 (Agilent, Santa Clara, California,
USA). Samples with a 28S/18S ribosomal peak ratio of
1.8–2.0 and a RIN number >7.0 were considered suitable
for labeling. RNA from one IHC specimen, two EHC spec-
imens, and three cases of GBC failed to meet this standard
and were discarded from the gene expression analysis. For
the remaining samples, 2 μg of total RNA was used for
cDNA synthesis using an oligo-dT-T7 primer and the
SuperScript Double-Stranded cDNA Synthesis Kit (Invit-
rogen, Carlsbad, California, USA). Synthesis, linear
amplification, and labeling of cRNA were accomplished
by in-vitro transcription using the MessageAmp aRNA Kit
(Ambion, Austin, Texas, USA) and biotinylated nucle-
otides (Enzo Diagnostics, New York, USA). Ten micro-
grams of labeled and fragmented cRNA were then
hybridized to the Human HG-U133A GeneChip (Affyme-
trix, Santa Clara, California, USA) at 45°C for 16 hours.
Post hybridization staining, washing were processed
according to manufacturer. Finally, chips were scanned
with a high-numerical aperture and flying objective lens
in the GS3000 scanner (Affymetrix). The image was quan-
tified using GeneChip Operating Software (GCOS) 1.4
(Affymetrix).
Array CGH profiling
Genomic DNA was extracted using the DNA/RNA prep kit
(Qiagen). DNA integrity was checked on a 1% agarose gel
and was intact in all specimens except one case of EHC. 3
μg of DNA was then digested and labeled by random
priming using RadPrime (Invitrogen) and Cy3 or Cy5-
dUTP. Labeled DNA was hybridized to 244 K CGH arrays
(Agilent) for 40 hours at 60°C. Slides were scanned and
images quantified using Feature Extraction 9.1 (Agilent).
Real-Time PCR
1 ug of total RNA was reverse-transcribed using the Ther-
moscript RT-PCR system (Invitrogen) at 52°C for 1 h. 20
ng of resultant cDNA was used in a Q-PCR reaction using
an iCycler (Biorad, Hercules, California, USA) and pre-
designed TaqMan ABI Gene expression Assays
(Hs00270424_m1 for CCNB2, Hs00938777_m1 for
CDC2, Hs00175938_m1 for CDKN1C, Hs01665258_m1
for DLC1, Hs01547109_m1 for FOSB, Hs99999032_m1
for IL6, s01118813_m1 for NR4A2, Hs00971643_g1 for
SRD5A1, Hs01014001_m1 for STAT1, Hs00426591_m1
for TYMS, Hs00197374_m1 for UBD). Primers were cho-
sen based on their ability to span the most 3' exon-exon
junction. Amplification was carried for 40 cycles (95C forJournal of Experimental & Clinical Cancer Research 2009, 28:62 http://www.jeccr.com/content/28/1/62
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15 sec, 60C for 1 min). To calculate the efficiency of the
PCR reaction, and to assess the sensitivity of each assay,
we also performed a 7 point standard curve (5,
1.7,0.56,0.19,0.062,0.021, and 0.0069 ng). Amounts of
target were interpolated from the standard curves and nor-
malized to HPRT (Hs99999909_m1).
Data Analysis
Image files were quantified using GCOS 1.1 to generate
the CEL files. These were normalized using the GC-RMA
package from the Bioconductor toolkit (Bioconductor,
Seattle, Washington State, USA). Expression values were
log (base 2) transformed for all subsequent analysis.
Unsupervised hierarchical clustering was done using a dis-
tance measure derived from the Pearson correlation (dis-
tance = (1-ρ)/2 were ρ is the correlation coefficient) and
average linkage options. To determine differentially
expressed genes a variant of the t- and F-tests were used as
implemented in the LIMMA toolkit (Bioconductor). To
account for multiple-testing the False Discovery Rate
(FDR) method was used. An FDR < 0.01 was considered
statistically significant. For clinicopathologic correlation,
a functional over-representation analysis was done on the
top 100 genes. p < 0.001 was considered significant.
For the array-CGH data, the raw images were quantified
with the Agilent Feature Extraction program and normal-
ized using a combination of intensity dependent and GC-
content dependent non-linear normalization procedure.
To determine significant changes in copy number, the Cir-
cular Binary Segmentation algorithm [14] was used with
alpha set to 0.001. Segments that had a log 2 ratio of
intensity greater than a sample dependent threshold and
a signal-to-noise ratio greater than 0.5 were considered
either amplified or deleted.
Results
Clinicopathologic Data
Frozen tissue was analyzed from 34 patients who under-
went surgery for biliary tract cancers between August 1993
and December 2005. 13 patients had IHC, 12 had EHC,
either at the bile duct bifurcation or in the mid or distal
bile duct, and 9 patients had tumors originating within
the gallbladder. Selected clinicopathologic features are
shown in Table 1. The median age of patients was 64
(range 46–88) and 20 (59%) patients were female. 31
(91%) patients had margin-negative resections, two (6%)
patients had margin-positive resections, and one (3%)
patient underwent biopsy only.
At last follow-up, 10 (29%) patients were alive without
evidence of disease, 3 (9%) patients were alive with recur-
rent disease and 19 (56%) died as a result of their disease.
One (3%) patient died of an unrelated cause and one
(3%) patient was lost to follow-up. The median follow-up
for surviving patients was 58 months (range 11–98). A
review of pathologic features revealed that 6 (18%)
patients had poorly differentiated tumors, 11 (32%)
patients had evidence of lymph node invasion, 15 (44%)
had vascular invasion, and 15 (44%) had perineural inva-
sion. The median tumor size was 11.0 cm (range 6.0 –
21.0) for IHC, 2.1 cm (range 1.5 – 5.9) for EHC, and 4.7
cm (range 1.5 – 12.0) for GBC (Table 1).
Gene Transcriptional Alterations in Biliary Carcinomas
We analyzed alterations in gene expression in EHC, IHC,
and GBC compared with non-cancerous bile duct or gall-
bladder controls using the Human Genome U133A Gene-
Chip. Figure 1 depicts the 40 top ranking overexpressed
and underexpressed genes for (a) extrahepatic cholangi-
ocarcinoma, (b) IHC, and (c) GBC. Ranking was based on
FDR values. Table 2 summarizes the extent of gene expres-
sion alterations for each type of biliary tract cancer. In the
EHC specimens, differential expression was noted in 545
genes compared with 2,354 in IHC and 1,281 in GBC (See
additional files 1, additional file 2, and additional file 3).
There was a near equal distribution of overexpressed and
underexpressed genes for each tumor type. However,
higher fold changes in expression levels were seen more
commonly with underexpressed genes. In particular,
depending on cancer subtype, 16–22% of genes with
decreased expression had greater than 10-fold changes
expression levels compared with controls. Conversely,
only 2–12% of genes with increased expression had alter-
ations of 10-fold or greater (Table 2).
Comparative Analysis of Biliary Cancer Subtypes
Unsupervised hierarchical clustering analysis revealed
that the three cancer subtypes did not cluster separately,
implying that there was no difference in the global gene
expression patterns between the biliary cancer subgroups.
Figure 1d depicts the top 40 up-regulated and down-regu-
lated genes for all cancers combined versus the 18 control
specimens. However, while the individual cancer sub-
types did not cluster separately, there was unique differen-
tial expression of many genes compared with normal
biliary epithelium in each cancer subtypes. The relation-
ship of gene transcriptional changes among the three bil-
iary cancer subtypes is depicted in a Venn diagram (Figure
1e). There was unique altered expression of 1633, 80, and
790 genes in IHC, EHC, and GBC, respectively. Overall,
165 probe sets were commonly differentially expressed in
all 3 cancer types (See additional file 4). Selected com-
monly differentially expressed genes are listed in Table 3.
Genomic Alterations in Biliary Carcinogenesis
To better understand the molecular pathogenesis of bil-
iary tract cancers we used an array based CGH analysis to
detect chromosomal areas of DNA copy number gain
(DNA copy number of 3 or greater) and loss (DNA copyJournal of Experimental & Clinical Cancer Research 2009, 28:62 http://www.jeccr.com/content/28/1/62
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Table 1: Clinicopathologic features of biliary tract cancer patients in this study
Biliary 
Cancer 
Subtype
Age Sex Lymph Node 
Invasion
Vascular 
Invasion
Perineural 
Invasion
Pathologic 
Differentiation
Size (cm) Follow-up 
(months)
Disease 
Statusa
Extrahepatic 77 F Present Absent Present Poor 2.0 42 DOD
Extrahepatic 57 F Present Present Present Moderate 1.5 61 DOD
Extrahepatic 60 M Present Present Present Poor 1.6 18 DOD
Extrahepatic 78 M Absent Present Present Poor 1.7 16 NED
Extrahepatic 81 F Absent Absent Absent Well 3.1 58 AWD
Extrahepatic 75 M Absent Present Absent Moderate 2.2 87 AWD
Extrahepatic 77 F Absent Absent Present Moderate 4.0 45 DOD
Extrahepatic 56 M Absent Absent Present Moderate 2.0 13 DOD
Extrahepatic 67 F Absent Absent Present Moderate 1.8 20 DOD
Extrahepatic 56 M Absent Present Present Moderate 4.8 40 DOD
Extrahepatic 62 M Absent Absent Absent Well 5.9 58 NED
Extrahepatic 47 M Absent Absent Present Moderate 2.3 6 DOD
Intrahepatic 64 M Absent Absent Absent Moderate 8.0 32 DOD
Intrahepatic 66 F Absent Present Absent Moderate 13.0 6 DOD
Intrahepatic 63 M Absent Present n/a Poor 9.9 14 DOD
Intrahepatic 56 M Absent Present Absent Moderate 11.0 18 DOD
Intrahepatic 70 M Absent Absent n/a Moderate 6.0 98 NED
Intrahepatic 53 F Absent Present Present Moderate 8.5 23 DOD
Intrahepatic 60 F Absent Absent Absent Poor 18.0 40 DOD
Intrahepatic 68 F Absent Absent Absent Moderate 12.0 33 DOD
Intrahepatic 50 M Absent Absent Absent Well 21.0 68 NED
Intrahepatic 60 F Absent Absent Absent Moderate 20.0 20 DOD
Intrahepatic 58 M Present Present Absent Moderate 9.0 38 DOD
Intrahepatic 46 F Present Present Absent Moderate 7.0 37 NED
Intrahepatic 87 F Present Absent Absent Moderate 14.0 11 NED
Gallbladder 58 F Present Absent Present Moderate 1.5 n/a n/a
Gallbladder 78 F Absent Absent Absent Moderate 12.0 77 NED
Gallbladder 79 F Absent Absent Absent Moderate 9.0 62 NED
Gallbladder 51 F Present Present Present Poor 4.7 24 AWD
Gallbladder 61 F Present Present Present Moderate 2.0 1 DUC
Gallbladder 88 F Absent n/ab n/a Moderate 8.7 2 DOD
Gallbladder 68 F Absent n/a n/a Moderate 3.5 82 NED
Gallbladder 78 F Present Present Present Moderate 9.0 3 DOD
Gallbladder 78 M Present Present Present Moderate 4.7 13 NED
Table 2: Summary of transcription mutations in subtypes of biliary tract carcinoma
Extrahepatic Cholangiocarcinoma Intrahepatic Cholangiocarcinoma Gallbladder Carcinoma
Number of transcriptional changes 545 2354 1281
Increased expression 200 1286 479
Decreased expression 345 1068 802
Increased > 20-fold 3 10 26
Increased > 10-fold 16 31 59
Decreased > 20-fold 22 88 72
Decreased > 10-fold 56 227 174Journal of Experimental & Clinical Cancer Research 2009, 28:62 http://www.jeccr.com/content/28/1/62
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number of 0 or 1) in the GBC, IHC, and EHC specimens.
Figure 2a depicts the chromosomal alterations for each
individual cancer specimen while Figure 2b–d represents
cumulative summaries of the chromosomal changes for
each cancer subtype. Cumulative chromosomal changes
for all biliary tract cancers combined are shown in Figure
2e.
Overall, patients with GBC exhibited the greatest genomic
instability while patients with IHC had the fewest ampli-
fications and deletions. In particular, the mean number of
chromosomal alterations per patient with GBC was 60.6
(range 17–110) with deletions (mean 35.0, range 9–55)
more frequent than amplifications (mean 25.6, range 8–
55). Patients with IHC had an average of 49.2 alterations
(range 11–101) in DNA copy number with slightly more
deletions (mean 26.9, range 8–80) than amplifications
(mean 22.2, range 2–47). EHC specimens had an average
of 43.8 chromosomal alterations (range 3–110) with an
average of 22.5 deletions (range 1–61) and 21.4 amplifi-
cations (range 1–62). Moreover, there was considerable
heterogeneity in the extent of chromosomal instability
between patients even within specific cancer subtypes. For
example, a number of patients within each cancer subtype
had mutations in nearly every chromosomal arm while
Gene Expression Alterations in Biliary Tract Cancers Figure 1
Gene Expression Alterations in Biliary Tract Cancers. Heat maps showing the top 40 overexpressed (red) and top 40 
underexpressed (green) genes for (a) EHC, (b) IHC, and (c) GBC. (d) All malignant subtypes were also combined for analysis 
and compared in terms of gene expression with benign bile duct and gallbladder controls. Genes were ranked based on FDR 
values. (e) A Venn diagram is used to depict the relationship of transcriptional changes among biliary cancer subtypes. There 
were 165 common genes with significantly altered expression in all three biliary tract cancer subtypes.Journal of Experimental & Clinical Cancer Research 2009, 28:62 http://www.jeccr.com/content/28/1/62
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other patients with the same tumor type had minimal
structural changes in their entire genome (Figure 2a).
While the cumulative pattern of chromosomal alterations
was highly variable, there appeared to be selected chro-
mosomal regions that were commonly altered across all
cancer subtypes. For example, a short segment of chromo-
some 1p was deleted in greater than 75% of patients with
GBC and IHC and nearly 50% of patients with EHC. Sim-
ilarly, segments of chromosomes 3p, 6q, 8p, 9p, and 14q
were commonly deleted across subtypes of biliary cancers.
Commonly amplified regions across cancer types include
segments of 1q, 3q, 5p, 7p, 7q, 8q, and 20q (Figure 2a–e).
Analysis of Transcriptional Changes in Commonly 
Unstable Genomic Regions
To further elucidate the pathogenesis of biliary tract can-
cers, we integrated the array based CGH data with our
gene expression profiling with by identifying gene expres-
sion alterations in regions of highest genomic instability.
Table 3: Selected genes with significantly altered expression in all three biliary cancer subtypes with the fold-change (Δ) in expression
Δ GB Δ Intra Δ Extra Gene Symbol Gene Title Chromosomal Location Functional Pathway
58 11 11 RRM2 ribonucleotide reductase M2 polypeptide chr2p25-p24 Nucleotide metabolism
41 6 10 PTTG1 pituitary tumor-transforming 1 chr5q35.1 Cell cycle
26 9 7 TYMS thymidylate synthetase chr18p11.32 Nucleotide metabolism
19 4 5 CDC2 Cell division cycle 2, G1 to S and G2 to M chr10q21.1 Cell cycle
18 4 7 CCNB2 cyclin B2 chr15q22.2 Cell cycle
12 3 4 RACGAP1 Rac GTPase activating protein 1 chr12q13.12 S1P Signaling
6 5 4 SHMT2 serine hydroxymethyltransferase 2 (mitochondrial) chr12q12-q14 Amino acid metabolism
3 3 3 PPAT phosphoribosyl pyrophosphate amidotransferase chr4q12 Purine metabolism
3 3 5 MCM6 MCM6 minichromosome maintenance deficient 6 chr2q21 Cell cycle
3 3 3 GMPS guanine monphosphate synthetase chr3q24 Nucleotide metabolism
2 2 2 RPS19 ribosomal protein S19 chr19q13.2 Ribosomal protein
2 3 2 CBX3 chromobox homolog 3 chr7p15.2 Circadian exercise
2 3 2 EIF2AK1 eukaryotic translation initiation factor 2-alpha 
kinase 1
chr7p22 Translation factor
2 2 2 EPRS glutamyl-prolyl-tRNA synthetase chr1q41-q42 Glutamate metabolism
2 2 2 PARP1 poly (ADP-ribose) polymerase family, member 1 chr1q41-q42 Apoptosis
2 2 2 SNRPD2 small nuclear ribonucleoprotein D2 polypeptide 
16.5 kDa
chr19q13.2 mRNA processing
-2 -2 -2 UBE2G2 ubiquitin-conjugating enzyme E2G 2 
(UBC7 homolog)
chr21q22.3 Proteolysis
-2 -2 -2 HNRPH1 Heterogeneous nuclear ribonucleoprotein H1 chr5q35.3 mRNA processing
-2 -3 -3 SUI1 putative translation initiation factor chr17q21.2 Translation factor
-3 -4 -3 RBM5 RNA binding motif protein 5 chr3p21.3 mRNA processing
-3 -2 -2 SFRS5 splicing factor, arginine/serine-rich 5 chr14q24 mRNA processing
-3 -3 -3 BCL2L2 BCL2-like 2 chr14q11.2-q12 Apoptosis
-4 -10 -7 CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) chr11p15.5 G1 to S cell cycle
-4 -8 -5 ZNF423 zinc finger protein 423 chr16q12 TGF-β signaling
-4 -3 -3 ACACB acetyl-Coenzyme A carboxylase beta chr12q24.11 Fatty acid synthesis
-4 -4 -3 RBM5 RNA binding motif protein 5 chr3p21.3 mRNA processing
-5 -7 -5 PRKAR2B protein kinase, cAMP-dependent, regulatory, type 
II, beta
chr7q22 G protein signaling
-5 -4 -4 ACACB acetyl-Coenzyme A carboxylase beta chr12q24.11 Fatty acid synthesis
-6 -4 -4 ITGA7 integrin, alpha 7 chr12q13 Cellular adhesion
-6 -7 -5 RGS2 regulator of G-protein signaling 2, 24 kDa chr1q31 Calcium regulation
-6 -9 -5 KLF9 Kruppel-like factor 9 chr9q13 Circadian exercise
-7 -7 -7 RPS6KA2 ribosomal protein S6 kinase, 90 kDa, polypeptide 2 chr6q27 Ribosomal protein
-7 -15 -10 ANK2 ankyrin 2, neuronal chr4q25-q27 Ribosomal protein
-8 -5 -6 ACACB acetyl-Coenzyme A carboxylase beta chr12q24.11 Fatty acid synthesis
-10 -4 -4 MYOM1 myomesin 1 (skelemin) 185 kDa chr18p11.32-p11.31 Muscle contraction
-11 -13 -8 ITGA7 integrin, alpha 7 chr12q13 Cellular adhesion
-13 -27 -14 CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2) chr11p15.5 G1 to S cell cycle
-61 -27 -26 ALDH1A2 aldehyde dehydrogenase 1 family, member A2 chr15q21.3 Metabolism/Biosynthesis
-67 -20 -7 CNN1 calponin 1, basic, smooth muscle chr19p13.2-p13.1 Muscle contraction
-85 -51 -18 CES1 carboxylesterase 1 chr16q13-q22.1 Irinotecan pathway
-102 -30 -24 DES desmin chr2q35 Muscle contractionJournal of Experimental & Clinical Cancer Research 2009, 28:62 http://www.jeccr.com/content/28/1/62
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To this end, we investigated the gene expression changes
in regions of the genome for which greater than 40% of
patients had either chromosomal gains or losses in each
cancer subtype (See additional files 5, additional file 6
and additional file 7). Selected alterations in gene expres-
sion within these unstable genomic regions are shown in
Table 4. Analysis of this data reveals that, as expected, a
positive correlation could be made between chromo-
somal deletion and the loss of gene expression. Con-
versely, there were no instances of increased gene
transcription in regions of chromosomal deletion. How-
ever, in regions of chromosomal amplification, both
increased and decreased gene transcription were seen with
similar frequency.
Validation of Findings
The Affymetrix U133A gene expression array data were
both internally and externally validated. First, a large
number of gene transcripts were represented by more than
one probe set in the array. In each case, the different
probes for each detected similar expression levels of tran-
script (See additional files 1, additional file 2, and addi-
tional file 3). This includes genes with altered expression
in EHC (i.e. CDKN1C, NR4A3, RBM5, SASH1), IHC
(ADH1B, GREM1, MCM4, NR4A2), and GBC
(HIST2H2AA, NUSAP1 RPS10, RPS19).
In addition, to externally validate our data, selected differ-
entially expressed genes were measured for transcript lev-
els in biliary carcinoma specimens and in normal biliary
epithelial controls using quantitative reverse transcriptase
PCR. We assayed 11 genes with differing biologic func-
tions and involvement in diverse molecular pathways but
with known importance in carcinogenesis. These included
genes which were overexpressed in EHC (SRDA21, STAT1,
UBD, TYMS), underexpressed in EHC (FOSB, CDKN1C,
IL6), overexpressed in IHC (SRDA21, STAT1, UBD,
TYMS), underexpressed in IHC (DLC1, NR4A2, IL6), and
overexpressed in GBC (UBD, TYMS, CDC2, CCNB2). PCR
data was normalized to HPRT which was expressed at sim-
ilar levels in both the cancerous and the control biliary
epithelium (not shown). Results are shown in Figures
(3a–f, 4g–k) and, for each gene tested, confirm the
Affymetrix U133A gene expression array data. The array-
Chromosomal Structural Mutations in Biliary Tract Cancers Figure 2
Chromosomal Structural Mutations in Biliary Tract Cancers. (a) A cumulative depiction of the copy number changes 
across the genome for all biliary cancer specimens is shown. Chromosomal number is listed on the left. Amplification is 
depicted in red and deletion in blue. White is unchanged from genomic DNA controls. Increased amplification or deletion 
within a cancer specimen is reflected in increased color intensity. The percentage of patient specimens that have either amplifi-
cations or deletions at each chromosomal loci is shown for (b) EHC, (c) IHC, (d) GBC, and (e) all biliary tract cancers com-
bined.Journal of Experimental & Clinical Cancer Research 2009, 28:62 http://www.jeccr.com/content/28/1/62
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Table 4: Selected changes in gene expression in commonly amplified or deleted regions of the genome for all biliary tract cancer 
specimens
Chromosomal Location % Amplified (+) or 
Deleted (-)
Fold Change Gene Title Gene Symbol Functional Properties
chr7p11 +42% 6.5 IGF-II mRNA-binding protein 3 IMP-3 RNA processing
chr7p13-p12 +45% 3.6 insulin-like growth factor 
binding protein 3
IGFBP3 Regulation of cell growth
chr5p15.33 +42% 3.5 thyroid hormone receptor 
interactor 13
TRIP13 Regulation of transcription
chr20q13.32 +45% 3.5 RAE1 RNA export 1 homolog RAE1 mRNA-nucleus export
chr7p21.1 +48% 3.2 basic leucine zipper and W2 
domains 2
BZW2 Translation initiation factor
chr7q22.1 +42% 3.0 origin recognition complex, 
subunit 5-like
ORC5L DNA replication initiation
chr20q13.3 +42% 2.7 ribosomal protein S21 RPS21 Protien biosysthesis
chr7p15 +42% 2.6 oxysterol binding protein-like 3 OSBPL3 Steroid metabolism
chr7p15-p13 +42% 2.5 v-ral simian leukemia viral 
oncogene homolog A
RALA GTPase mediated signal 
transduction
chr20q13.2 +48% -6.9 docking protein 5 DOK5 Insulin receptor binding
chr7q11.2 +42% -7.8 CD36 antigen CD36 Lipid metabolism
chr7q21.1 +42% -7.9 ATP-binding cassette, sub-
family B, member 1
ABCB1 Cell surface transport
chr7p21 +45% -9.1 interleukin 6 IL6 Acute phase response
chr20q11.23 +42% -10.0 myosin, light polypeptide 9, 
regulatory
MYL9 Regulation of muscle 
contraction
chr7q31-q32 +42% -10.9 solute carrier family 13, 
member 1
SLC13A1 Ion transport
chr20q13.13 +45% -14.7 prostaglandin I2 synthase PTGIS Prostaglandin biosynthesis
chr7q31 +42% -38.1 solute carrier family 26, 
member 3
SLC26A3 Transcription factor activity
chr6q22.1 -55% -46.2 phospholamban PLN Calcium ion transport
chr9q22 -42% -41.0 osteoglycin OGN Growth factor activity
chr6q24-q25 -58% -19.2 A kinase anchor protein 12 AKAP12 Signal transduction
chr14q24.3 -42% -17.1 v-fos FBJ murine osteosarcoma 
viral oncogene homolog
FOS DNA methylation
chr14q32.1 -45% -13.6 fibulin 5 FBLN5 Cell-matrix adhesion
chr3p26-p25 -45% -10.0 inositol 1,4,5-triphosphate 
receptor, type 1
ITPR1 Cation transport
chr3p13 -52% -9.2 PDZ domain containing RING 
finger 3
PDZRN3 Protein ubiquitination
chr3p21.1 -58% -8.9 TU3A protein TU3A Regulation of cell growth
chr14q32.1 -48% -8.5 serine proteinase inhibitor, 
clade A, member 5
SERPINA5 Endopeptidase inhibitor
chr3p22-p21.3 -58% -8.5 C-type lectin domain family 3, 
member B
CLEC3B Skeletal development
chr9p13.2-p13.1 -42% -8.3 tropomyosin 2 TPM2 Muscle development
chr14q32 -48% -8.1 delta-like 1 homolog DLK1 Calcium ion binding
chr6q27 -58% -6.5 ribosomal protein S6 kinase, 90 
kDa, polypeptide 2
RPS6KA2 Amino acid phosphorylation
chr6q24-q25 -52% -6.2 pleiomorphic adenoma gene-
like 1
PLAGL1 Regulation of transcription
chr9p13-p12 -42% -5.8 reversion-inducing-cysteine-rich 
protein with kazal motifs
RECK Cell cycle regulation
chr3p21.2-p21.1 -61% -5.4 aminomethyltransferase AMT Glycine catabolism
chr6pter-qter -48% -5.4 transcription factor 21 TCF21 Regulation of transcription
chr9q13 -42% -5.1 Kruppel-like factor 9 KLF9 Regulation of transcription
chr6q23 -48% -3.8 serum/glucocorticoid regulated 
kinase
SGK Amino acid phosphorylation
chr3p26-p25 -45% -3.6 inositol 1,4,5-triphosphate 
receptor, type 1
ITPR1 Cell cycle regulation
chr1p36.13-p36.11 -55% -3.2 neuroblastoma, suppression of 
tumorigenicity 1
NBL1 calcium ion transport
chr6q22 -55% -2.6 mannosidase, alpha, class 1A, 
member 1
MAN1A1 Carbohydrate metabolism
chr3p22 -48% -2.5 transforming growth factor, 
beta receptor II
TGFBR2 Regulation of cell 
proliferationJournal of Experimental & Clinical Cancer Research 2009, 28:62 http://www.jeccr.com/content/28/1/62
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based CGH results were internally validated by correla-
tion of the X chromosome copy number with patient gen-
der.
Correlation of Gene Expression Profiles with 
Clinicopathologic Features
To determine whether certain clinicopathologic features
are associated with specific gene expression changes in bil-
iary carcinomas, we performed over-representation analy-
ses by determining whether certain functional gene
categories were over-represented among the top 100 rank-
ing genes (by FDR) with altered expressing in patients
with specific clinicopathologic features. Altered expres-
sion of genes associated with functional categories related
to ribosomal structure, cellular and protein biosynthesis
and cellular metabolism were significantly associated
with high grade tumors (See additional file 8). Similarly,
a strong correlation could be made between vascular inva-
sion and mutated expression of genes involved with elec-
tron transport and metabolism (See additional file 9).
Perineural invasion was correlated with altered expression
of genes in the functional categories associated with mito-
chondrial structure and electron transport (See additional
file 10). There was no significant association between
gene expression patterns and lymph node invasion. Simi-
larly, we did not find a significant correlation between
functional gene category over-representation and survival.
Real-Time PCR Based Validation of Gene Expression Findings Figure 3
Real-Time PCR Based Validation of Gene Expression Findings. To confirm the gene expression changes in biliary tract 
cancers identified on microarray analysis, selected genes were tested in tumor and control specimens by RT PCR and normal-
ized to HRPT which is similarly expressed in tumors and normal biliary epithelia. Results are shown for (a) TYMS, (b) UBD, (c) 
STAT1, (d) SRD5A1, (e) CCNB2, (f) CDC2.Journal of Experimental & Clinical Cancer Research 2009, 28:62 http://www.jeccr.com/content/28/1/62
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Discussion
The molecular pathogenesis of biliary tract cancers is
poorly understood. By performing immunohistochemical
analysis of more than 125 surgically resected cases of bil-
iary tract carcinoma, we have previously shown altered
cell cycle regulatory protein expression in biliary tact can-
cers [13]. Our current findings also show mutated expres-
sion of a large number of cell cycle regulators including
UBD, BCL2L2, CDC2, MCM2, and CDKN1C in all sub-
types. Similarly, Kang et al. [15] found that expression of
G1-S modulators were commonly mutated in 42 cases of
IHC. Total loss of p16, p27, and Rb were detected at rates
of in 36%, 31%, 12%, respectively, in cancer specimens.
Furthermore, in the above study, even in 7 of 13 cases of
biliary dysplasia, without frank carcinoma, abnormal
expression of p53, cyclin D1 or p16 was detected. Kim et
al. [16] reported that the mutation of the p53, p16, and K-
ras genes occurred at rates of 36%, 31% and 20%, respec-
tively, in GBC. A further finding of the above study was
that 100% of GBCs and 80% of adenomas displayed loss
of heterozygosity at a minimum of one locus which is
consistent with our CGH results. Chang et al. [17] studied
loss of heterozygosity in 32 cases of GBC and 11 cases of
dysplasia. Loss of one allele was identified on chromo-
somes 5q (55%) and 17p (40%) in the dysplastic cases
and on chromosomes 3p (52%), 5q (66%), 9p (52%),
and 17p (58%) in the carcinomas. Loss of heterozygosity
on multiple chromosomes was significantly more fre-
Real-Time PCR Based Validation of Gene Expression Findings Figure 4
Real-Time PCR Based Validation of Gene Expression Findings. To confirm the gene expression changes in biliary tract 
cancers identified on microarray analysis, selected genes were tested in tumor and control specimens by RT PCR and normal-
ized to HRPT which is similarly expressed in tumors and normal biliary epithelia. Results are shown for (g) IL6, (h) FOSB, (i) 
CDKN1C, (j) NR4A2, and (k) DLC.Journal of Experimental & Clinical Cancer Research 2009, 28:62 http://www.jeccr.com/content/28/1/62
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quent in patients with metastatic disease than in cases
without metastases. In the current report, we similarly
found that segments of 3p and 9p were commonly
deleted across all subtypes of biliary cancers. However, we
additionally discovered that segments of 6q, 8p, and 14q
were commonly deleted across subtypes of biliary cancers
There is increasing evidence that overexpression of tyro-
sine kinase growth factor receptors such as ErbB-2, epider-
mal growth factor receptor (EGFR), and Met play
important roles in the development of biliary tract carci-
nomas. Nakasawa et al. [18] studied tyrosine kinase recep-
tor proteins expression by in 221 biliary tract carcinomas
and found that overexpression of ErbB-2 was found in
16% of carcinomas of the gallbladder and a slightly lower
percentage of extrahepatic bile duct tumors. ErbB-2 gene
amplification was present in 79% of cases. Overexpres-
sion of EGFR was found in 8% of tumors and was also
associated with a high frequency of gene amplification
(77%). Met overexpression was most frequent in IHC
(21.4%) but was not associated with gene amplification.
Microsatellite instability also appears to be a critical factor
in selected cases of biliary carcinogenesis. Roa et al. [19]
performed microsatellite analysis on 59 frozen GBC spec-
imens using 13 different markers. They found evidence of
microsatellite instability in equal proportions in early and
late cancers, and it was also found in premalignant
lesions, indicating that inactivation of mismatch repair
genes occurs early in gallbladder carcinogenesis.
In addition to finding that a large proportion of differen-
tially expressed genes in this study involved in cell cycle
regulation and apoptosis, we also discovered a dispropor-
tionate number of mutated genes that control transcrip-
tional regulation, RNA procession, cellular signaling, or
are involved with cytoskeletal structure, extracellular
matrix, and cellular adhesion. Differentially expressed
genes involved with transcriptional regulation include
STAT1, NARG1, HOXC6, and MMP11. Important genes
involved with signal transduction with altered expression
include CXCL5, ECT2, GPRC5A, MELK, and CKS2. Dys-
regulated genes involved with cytoskeleton, extracellular
matrix and cellular adhesion include ITGA7,  LAMB3,
CECAM5, KRT6B, and CLDN18.
The findings of the present study will serve as a resource
for other investigators in this area as we have indentified
many potential targets for therapeutic intervention. As an
example, we found that TYMS, which encodes an enzyme
that catalyzes 5-fluorouracil, was overexpressed 7.2 –
26.0-fold depending on biliary cancer subtype. TYMS
expression is correlated inversely with clinical response to
5-fluorouracil-based chemotherapy and the overexpres-
sion may explain the futility of 5-fluorouracil-based
chemotherapy for biliary carcinomas [20].
We also found that a number of genes in the ubiquitin
pathway had altered expression in each cancer subtypes.
For example, more than 20 ubiquitin-related genes had
significantly altered expression IHC. In GBC, UBD was
overexpressed more than 200-fold and UBE2C was over-
expressed nearly 15-fold. Ubiquitin and ubiquitin-like
proteins are signaling messengers that regulate a variety of
cellular processes including cell proliferation, cell cycle
regulation, DNA repair, and apoptosis. There is accumu-
lating evidence that deregulation of this pathway as a
result of mutations or altered expression of ubiquitylating
or de-ubiquitylating enzymes as well as of Ub-binding
proteins affect crucial mediators of these functions and are
underlie the pathogenesis of several human malignancies
[21]. A variety of inhibitors of the ubiquitin system are
currently being experimentally tested in clinical trials with
promising early results [22]. These data suggests these
inhibitors may have applicability as adjuvants in treating
patients with biliary tract carcinomas.
Another promising target uncovered in this report is
STAT-1 which was overexpressed nearly 9-fold in cases of
cholangiocarcinoma. The Signal Transducers and Activa-
tor of Transcription (STAT) proteins regulate many aspects
of cell growth, survival and differentiation. The transcrip-
tion factors of this family are activated by the Janus Kinase
JAK and dysregulation of this pathway has been observed
in primary tumors and leads to increased angiogenesis,
metastases, enhanced survival of tumors, and immuno-
suppression [23,24]. A number of JAK/STAT pathway
inhibitors are being tested in pre-clinical studies and their
application to cancers of the biliary tract may prove prom-
ising [25].
Conclusion
Both gene expression and CGH data support an overlap-
ping pathogenetic mechanism for all subsets of biliary
tract cancers. However, exceptional diversity of muta-
tional findings between individual patient specimens is
also apparent. Functional over-representation analysis
revealed a significant association between altered expres-
sion of genes involved with regulation of cellular metabo-
lism and biosynthesis and high pathologic grade. Vascular
invasion was associated with mutated expression of genes
involved with electron transport and cellular metabolism.
CGH analysis revealed that short segments of chromo-
somes 1p, 3p, 6q, 8p, 9p, and 14q were commonly
deleted across all cancer subtypes while commonly ampli-
fied regions included segments of 1q, 3q, 5p, 7p, 7q, 8q,
and 20q. The data also offer opportunities to uncover
potential targets for experimental therapeutics.
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